ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Efficiency of ledipasvir/sofosbuvir threatment in hepatitis C virus
Abstract
Aims: This study analyzes the efficiency of a combination of ledipasvir/sofosbuvir (LED/SOF), a newly developed direct-acting antiviral agent, in patients infected with hepatitis C virus (HCV) with or without a treatment history [pegile-interferon±ribavirin (PEG-IFN±RBV)] who subsequently developed recurrence.
Methods: Files of hepatitis C-infected patients who received LED/SOF treatment for 3-6 months with recurrence or without a treatment history (PEG-IFN±RBV) before admission to Gülhane Training and Research Hospital between 06.06.2016 and 23.05.2018 were taken into account.
Results: This study included 45 patients, 20 of whom were female (44.4%) and 25 of whom were male (55.6%). Among those patients, 22 were administered PEG-IFN±RBV treatment and experienced recurrence, whereas 23 had no previous treatment history. Age; sex; 6-month aspartate aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, and albumin, international normalized ratio (INR), hemoglobin (HGB) and thrombocyte (PLT) values; and 1-, 2- and 6-month-old HCV-RNA levels were evaluated in this study. When the pretreatment HCV-RNA levels and the 1st, 2nd and 6th month HCV-RNA levels were compared, the decrease in the values was statistically significant (p<0.05, p<0.05, p<0.05, p<0.05). The initial and 6-month AST, ALT, GGT, and ALB levels and the PLT were statistically significant (p<0.05, p<0.05, p<0.05, p<0.05, p<0.05, p<0.05, respectively).
Conclusion: LED/SOF treatment in patients with or without HCV infection treatment experience was found to be reliable and successful.

Keywords : RBV, PEG-IFN, HCV-RNA, LED/SOF

Download Article


1. Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi:10.1016/ j.jhep.2018.03.026
2. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-1026. doi:10.1016/j.cmi. 2015.06.028
3. Chen J, Han Y, Xu C, Xiao T, Wang B. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev. 2015;24(2):89-99. doi:10.1097/CEJ.0000000000000038
4. Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64(6):1217-1223. doi:10.1016/j.jhep. 2016.01.034
5. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593. doi:10.1001/jama.2012.144878
6. Kew MC. Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis. J Viral Hepat. 2006;13(3):145-149. doi:10.1111/j.1365-2893.2005.00686.x
7. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology. 1997;112(1): 184-187. doi:10.1016/s0016-5085(97)70233-6
8. Nahon P, Bourcier V, Layese R, et al. Risk factors and long-term outcomes in chronic hepatitis C. Gastroenterology. 2017;152(1):142-156.
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-538. doi:10.1016/j.jhep.2006.05.013
10. Borba HHL, Wiens A, Steimbach LM, et al. Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag. 2017; 13:59-64. doi:10.2147/TCRM.S124663
11. Younossi ZM, Stepanova M, Esteban R, et al. Superiority of interferon-free regimens for chronic hepatitis C: the effect on health-related quality of life and work productivity. Medicine (Baltimore). 2017;96(7):e5914. doi:10.1097/MD.0000000000005914
12. Spengler U. Direct antiviral agents (DAAs). A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. doi:10. 1016/j.pharmthera.2017.10.009
13. Sugawara Y, Hibi T. Direct-acting agents for hepatitis C virus before and after liver transplantation. Biosci Trends. 2018;11(6):606-611. doi:10. 5582/bst.2017.01293
14. European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199-236.
15. Nakano T, Lau GMG, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2012;32(2):339-345. doi:10.1111/j.1478-3231.2011. 02684.x
16. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57. doi:10.1016/j.jhep.2014.07. 027
17. Abacioglu YH, Davidson F, Tuncer S, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat. 1995;2(6):297-301. doi:10.1111/j.1365-2893.1995.tb00045.x
18. Chen JJ, Lee PL, Chiu HC, Tung HD, Chiu YC, Cheng PN. Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan. J Gastroenterol Hepatol. 2020;35(3):467-472. doi:10.1111/jgh.14845
19. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898. doi:10.1056/NEJMoa1402454
20. Del Rio-Valencia JC, Asensi-Diez R, Tamayo-Bermejo R, Mu&ntilde;oz-Castillo I. Effectiveness of 12-week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C. Rev Esp Quimioter. 2019;32(4):296-302.
21. Gane EJ, Hyland RH, Yang Y, et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology. 2017;152(6):1366-1371. doi:10.1053/j.gastro. 2017.01.017
22. Zeng QL, Xu GH, Zhang JY, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J Hepatol. 2017;66(6):1123-1129. doi:10.1016/j.jhep.2017.01.025
23. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454-1461.e1. doi:10.1053/j.gastro.2015.07.063
24. Corma-G&oacute;mez A, Mac&iacute;as J, Merino Mu&ntilde;oz D, et al. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. J Infect. 2019;79(1):30-35. doi:10.1016/j.jinf.2019.05.005
25. Akin M, Buldukoglu OC, Adanir H, Suleymanlar I, Dincer D, Yildirim B. Effectiveness and safety of sofosbuvir/ledipasvir&plusmn;ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: a single-center experience. SAGE Open Med. 2018;6:2050312118781416. doi:10.1177/2050312118781416
26. Schiff ER, Maddrey WC, Sorrell MF, eds. Schiff&rsquo;s Diseases of the Liver. 17th ed. Wiley; 2012:582-634.
Article available in :
Volume 3, Issue 3, 2025
Page : 48-52
https://doi.org/10.51271/ICJIM-0058
Article Information
Received : 05 Şub 2025
Accepted : 02 Haz 2025
Published : 29 Ağu 2025
Corresponding Author :

Elif Bilgiç: Department of Internal Medicine, Gülhane Training and Research Hospital, Ankara, Turkiye

[email protected]
Citation : Bilgiç E, Çağın YF, Menteş O, Aladağ M. Efficiency of ledipasvir/sofosbuvir treatment in hepatitis C virus infection. Intercont J Int Med. 2025;3(3):48-52.

Read: 65
Download : 555
Cited: 0
_Footer